These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15001974)

  • 1. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity.
    Duguay Y; Báár C; Skorpen F; Guillemette C
    Clin Pharmacol Ther; 2004 Mar; 75(3):223-33. PubMed ID: 15001974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients.
    Holthe M; Rakvåg TN; Klepstad P; Idle JR; Kaasa S; Krokan HE; Skorpen F
    Pharmacogenomics J; 2003; 3(1):17-26. PubMed ID: 12629580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy.
    Holthe M; Klepstad P; Zahlsen K; Borchgrevink PC; Hagen L; Dale O; Kaasa S; Krokan HE; Skorpen F
    Eur J Clin Pharmacol; 2002 Aug; 58(5):353-6. PubMed ID: 12185559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability in UDP-glucuronosyltransferase genes and morphine metabolism: observations from a cross-sectional multicenter study in advanced cancer patients with pain.
    Fladvad T; Klepstad P; Langaas M; Dale O; Kaasa S; Caraceni A; Skorpen F
    Pharmacogenet Genomics; 2013 Mar; 23(3):117-26. PubMed ID: 23277092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease.
    Darbari DS; van Schaik RH; Capparelli EV; Rana S; McCarter R; van den Anker J
    Am J Hematol; 2008 Mar; 83(3):200-2. PubMed ID: 17724700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants.
    Yang ZZ; Li L; Wang L; Yuan LM; Xu MC; Gu JK; Jiang HD; Yu LS; Zeng S
    Acta Pharmacol Sin; 2017 Aug; 38(8):1184-1194. PubMed ID: 28552915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene.
    Innocenti F; Liu W; Fackenthal D; Ramírez J; Chen P; Ye X; Wu X; Zhang W; Mirkov S; Das S; Cook E; Ratain MJ
    Pharmacogenet Genomics; 2008 Aug; 18(8):683-97. PubMed ID: 18622261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients.
    Kuypers DR; Naesens M; Vermeire S; Vanrenterghem Y
    Clin Pharmacol Ther; 2005 Oct; 78(4):351-61. PubMed ID: 16198654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms and haplotypes of the UDP-glucuronosyltransferase 2B7 gene promoter.
    Hu DG; Meech R; Lu L; McKinnon RA; Mackenzie PI
    Drug Metab Dispos; 2014 May; 42(5):854-62. PubMed ID: 24561451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphisms in the 5'-flanking region of human UDP-glucuronosyltransferase 2B7 affect the Nrf2-dependent transcriptional regulation.
    Nakamura A; Nakajima M; Higashi E; Yamanaka H; Yokoi T
    Pharmacogenet Genomics; 2008 Aug; 18(8):709-20. PubMed ID: 18622263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.
    van Agteren M; Armstrong VW; van Schaik RH; de Fijter H; Hartmann A; Zeier M; Budde K; Kuypers D; Pisarski P; Le Meur Y; van der Werf M; Mamelok RD; Oellerich M; van Gelder T
    Ther Drug Monit; 2008 Aug; 30(4):439-44. PubMed ID: 18641546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1.
    Aklillu E; Carrillo JA; Makonnen E; Hellman K; Pitarque M; Bertilsson L; Ingelman-Sundberg M
    Mol Pharmacol; 2003 Sep; 64(3):659-69. PubMed ID: 12920202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers.
    Lévesque E; Delage R; Benoit-Biancamano MO; Caron P; Bernard O; Couture F; Guillemette C
    Clin Pharmacol Ther; 2007 Mar; 81(3):392-400. PubMed ID: 17339869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7.
    Innocenti F; Iyer L; Ramírez J; Green MD; Ratain MJ
    Drug Metab Dispos; 2001 May; 29(5):686-92. PubMed ID: 11302935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Environmental and genetic factors associated with morphine response in the postoperative period.
    Coulbault L; Beaussier M; Verstuyft C; Weickmans H; Dubert L; Trégouet D; Descot C; Parc Y; Lienhart A; Jaillon P; Becquemont L
    Clin Pharmacol Ther; 2006 Apr; 79(4):316-24. PubMed ID: 16580900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine.
    Sawyer MB; Innocenti F; Das S; Cheng C; Ramírez J; Pantle-Fisher FH; Wright C; Badner J; Pei D; Boyett JM; Cook E; Ratain MJ
    Clin Pharmacol Ther; 2003 Jun; 73(6):566-74. PubMed ID: 12811366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain-derived neurotrophic factor involved epigenetic repression of UGT2B7 in colorectal carcinoma: A mechanism to alter morphine glucuronidation in tumor.
    Yang ZZ; Li L; Xu MC; Ju HX; Hao M; Gu JK; Jim Wang ZJ; Jiang HD; Yu LS; Zeng S
    Oncotarget; 2017 Apr; 8(17):29138-29150. PubMed ID: 28418861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter activity of human tissue inhibitor of metalloproteinase 2 gene with novel single nucleotide polymorphisms.
    Hegab AE; Sakamoto T; Uchida Y; Nomura A; Ishii Y; Morishima Y; Mochizuki M; Kimura T; Saitoh W; Iizuka T; Kiwamoto T; Sekizawa K
    Respirology; 2005 Jan; 10(1):27-30. PubMed ID: 15691234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Octamer transcription factor-1 enhances hepatic nuclear factor-1alpha-mediated activation of the human UDP glucuronosyltransferase 2B7 promoter.
    Ishii Y; Hansen AJ; Mackenzie PI
    Mol Pharmacol; 2000 May; 57(5):940-7. PubMed ID: 10779377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy.
    Hirota T; Ieiri I; Takane H; Sano H; Kawamoto K; Aono H; Yamasaki A; Takeuchi H; Masada M; Shimizu E; Higuchi S; Otsubo K
    Drug Metab Dispos; 2003 May; 31(5):677-80. PubMed ID: 12695358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.